Navigating the Gaudium IVF IPO: A Deep Dive for Informed Investors
The Indian capital market is buzzing with anticipation as Gaudium IVF & Women Health Ltd. prepares to launch its Initial Public Offering (IPO). For retail and institutional investors alike, understanding the nuances of this offering—from the company's operational strength to its financial health—is crucial before making any investment decisions. This comprehensive analysis breaks down everything you need to know about the Gaudium IVF IPO, ensuring you have the insights required for sound participation.
Understanding Gaudium IVF & Women Health Ltd.
Established in March 2015, Gaudium IVF has rapidly grown into a significant player in the Assisted Reproductive Technology (ART) and In Vitro Fertilization (IVF) space across India. The company utilizes a robust hub-and-spoke model to deliver specialized fertility services.
Core Business and Reach
- Operates over thirty locations, structured as seven central hubs and twenty-eight spokes.
- Maintains established centres in key metropolitan areas like Delhi (two centres), Mumbai, Bangalore, and Patna.
- Offers comprehensive specialized fertility treatments including IVF, ICSI, IUI, and ovulation induction.
- Serves an international patient base, including clients from Canada, the UK, the USA, Kenya, South Africa, and Oman.
Competitive Edge: Why Gaudium Stands Out
The company's competitive advantages are centered around operational excellence and patient care:
- Strong emphasis on a patient-centric approach tailored to individual fertility needs.
- Utilization of advanced technology, such as next-gen INTEGRA Ti labs for ICSI procedures.
- High technical proficiency in USG Guided Services.
- Adoption of an Asset-Light Business Model, allowing for scalable expansion.
- An expert team dedicated to delivering complex gynaecological care and high-risk pregnancy management.
Gaudium IVF IPO Snapshot: Key Offering Details
This is a book-building issue totaling ₹165.00 crores, comprising both a fresh issue component and an Offer for Sale (OFS).
IPO Structure and Size Summary
| Metric | Details |
|---|---|
| Total Issue Size | 2,08,86,200 Equity Shares (Up to ₹165 Cr) |
| Fresh Issue Component | 1,13,92,500 Shares (Up to ₹90 Cr) |
| Offer for Sale (OFS) | 94,93,700 Shares (Up to ₹75 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing Exchanges | BSE, NSE |
Investment Details: Price Band and Application Structure
The IPO price band determines the potential cost per share, while the lot size dictates the minimum investment required.
Pricing and Valuation Metrics
| Parameter | Value |
|---|---|
| Face Value | ₹5 per share |
| Price Band (Per Share) | ₹75 to ₹79 |
| Pre-IPO Market Capitalization | ₹575.02 Crore |
| Post-IPO P/E Ratio (Approx.) | 22.99x |
Lot Size and Investor Categories
Investors apply in predefined lots. The minimum investment for a retail individual investor is based on the upper price band.
| Investor Category | Lots | Shares | Minimum Investment (Approx.) |
|---|---|---|---|
| Retail (Minimum Bid) | 1 | 189 | ₹14,931 |
| S-HNI (Minimum Bid) | 14 | 2,646 | ₹2,09,034 |
| B-HNI (Minimum Bid) | 67 | 12,663 | ₹10,00,377 |
IPO Timetable: Crucial Dates to Remember
A clear understanding of the timeline is essential for timely bidding and tracking allotment status.
Tentative IPO Schedule
| Milestone | Date (Tentative) |
|---|---|
| IPO Opening Date | Friday, February 20, 2026 |
| IPO Closing Date | Tuesday, February 24, 2026 |
| Allotment Finalization | Wednesday, February 25, 2026 |
| Initiation of Refunds | Wednesday, February 25, 2026 |
| Credit of Shares to Demat A/c | Thursday, February 26, 2026 |
| Tentative Listing Date | Friday, February 27, 2026 |
Application Progress Simulation (Conceptual Example)
While live subscription data is dynamic, here is a visual representation of how subscription progress is tracked:
*(Note: The actual subscription status will be monitored live closer to the closing date on specialized IPO tracking portals.)*
Reservation Quotas
The IPO allocation is divided among different investor classes as per SEBI guidelines:
| Investor Category | Shares Offered Percentage |
|---|---|
| Qualified Institutional Buyers (QIB) | Not more than 50.00% of the Net Issue |
| Non-Institutional Investors (NII) | Not less than 15.00% of the Net Issue |
| Retail Individual Investors (RII) | Not less than 35.00% of the Net Issue |
Financial Health and Performance Indicators
Reviewing the Restated Consolidated Financials provides insight into the company’s recent performance trajectory leading up to the IPO.
Key Financial Results (Amounts in ₹ Crore)
| Period Ended | Sep 30, 2025 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Total Income | 49.75 | 70.96 | 48.15 | 44.26 |
| Profit After Tax (PAT) | 12.51 | 19.13 | 10.32 | 13.53 |
| EBITDA | 18.95 | 28.63 | 19.27 | 20.07 |
| Total Borrowing | 22.51 | 18.93 | 15.73 | 9.78 |
Key Performance Indicators (KPIs) Snapshot
These ratios indicate efficiency and profitability:
| KPI | Sep 30, 2025 | Mar 31, 2025 |
|---|---|---|
| Return on Equity (ROE) | 21.25% | 41.31% |
| Return on Capital Employed (ROCE) | 21.03% | 39.70% |
| PAT Margin | 25.14% | 26.96% |
| Debt/Equity Ratio | 0.38 | 0.41 |
Shareholding Structure and Promoter Details
Understanding who controls the company and how the shareholding structure changes post-IPO is vital for assessing management stability and public float.
Promoter Holding Transition
| Holding Status | Shares Held (%) |
|---|---|
| Promoter Holding (Pre-Issue) | 99.99% |
| Promoter Holding (Post-Issue) | 71.30% |
The primary promoters of Gaudium IVF & Women Health Ltd. are Dr. Manika Khanna, Dr. Peeyush Khanna, and Vishad Khanna.
Objective of the Issue Proceeds
The company intends to strategically deploy the net proceeds to fuel growth initiatives and strengthen its balance sheet.
| Use of Proceeds | Estimated Amount (₹ Cr.) |
|---|---|
| Funding Capital Expenditure for New IVF Centres | 50.00 |
| Repayment/Prepayment of Outstanding Loans | 20.00 |
| General Corporate Purpose | Remainder |
Preliminary SWOT Analysis of Gaudium IVF
A balanced view requires assessing internal strengths and weaknesses alongside external opportunities and threats related to the IVF sector.
Strengths
- Asset-light business model facilitating rapid expansion.
- Strong presence in major Indian cities through established hubs.
- Experienced team and use of modern technology in procedures.
Weaknesses
- High reliance on promoter holding pre-IPO (though reduced post-IPO).
- Recent increase in total borrowings compared to previous fiscal years.
Opportunities
- Growing awareness and acceptance of ART/IVF treatments across India and internationally.
- Expansion into Tier 2/3 cities via the spoke model.
Threats
- Intense competition in the specialized healthcare sector.
- Potential regulatory changes impacting fertility treatments.
Key Intermediaries for the IPO
Reliable intermediaries ensure the smooth execution and compliance of the public offering.
Book Running Lead Manager (BRLM)
- Sarthi Capital Advisors Pvt.Ltd.
Registrar and Share Transfer Agent
This entity manages allotment and refund processes.
- Bigshare Services Pvt.Ltd.
- Contact: +91-22-6263 8200, ipo@bigshareonline.com
How to Participate in the Gaudium IVF IPO
Application for the IPO can typically be done through ASBA (via net banking) or via UPI through a registered brokerage account. For investors using popular discount brokers, the process generally involves similar digital steps.
If utilizing a platform like Zerodha (a frequently compared discount broker), the steps generally involve:
- Logging into the respective broker console/platform.
- Navigating to the IPO section.
- Selecting the 'Gaudium IVF IPO' and placing a bid (entering UPI ID, quantity, and price).
- Approving the payment mandate received on the linked UPI application.
It is recommended that applicants confirm the exact procedure with their respective brokers.
Company Contact Information
For direct correspondence regarding corporate matters:
- Address: B1/51, Janak Puri, B-1, New Delhi, New Delhi, 110058
- Phone: 011-4885 8585
- Email: compliance@gaudiumivfcentre.com
- Website: https://www.gaudiumivfcentre.com/
Final Takeaways on the Gaudium IVF IPO
The Gaudium IVF IPO presents an opportunity to invest in a specialized healthcare segment showing strong growth potential, backed by a scalable operational model. While the financials indicate healthy profitability margins (PAT Margin around 25-27% recently), potential investors should weigh the valuation multiples against the sector peers and the substantial capital expenditure planned for future expansion. Thorough due diligence, perhaps by examining the Red Herring Prospectus (RHP) in detail, is always advisable before committing funds to any public offering.